LENZ

LENZ Therapeutics, Inc. (LENZ) | Rumor.io

LENZ Therapeutics

LENZ

Attention (50-day avg)0%

Attention rank (50-day avg)#1,589

Bullish sentiment (50-day avg)80%

Price to earnings ratio48

Market capitalization124.4M

Earnings per share-4.13

Dividend yield (TTM)—

Revenue (annual)19.1M

Net income (annual)-82.1M

Social

What share of all stock conversation is about LENZ?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Aug 12

LENZ Therapeutics, Inc. reported strong Q2 performance, with prescriptions increasing 8-10% quarter-over-quarter and 36-46% annualized growth.
The company's earnings call showed a 45% month-over-month increase in July prescriptions, with 60% of customers buying multiple packs.
Analyst Biren Amin downgraded LENZ's price target from $12 to $7, citing a decrease in potential upside change and a rating of Neutral.

Generated by AI

Sentiment

Of the messages about LENZ that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	50%	80% +0.83	75.68% -15.57
Bearish	0%	50%	20% -0.83	24.32% +15.57

Mar 15

LENZ Therapeutics, Inc. has a major uptrend on all technicals, with a strong possibility of reaching $5.
The company's merger is complete, a dividend is being paid out, and shorts have to pay $1.03 per short share, making it a favorable situation for the stock.
The FDA approval of LENZ's phase 3 results could significantly increase the stock's value, potentially exceeding $3, and investors should hold onto the stock for at least 1-2 years to reap the benefits.

Generated by AI

Topics

Of the messages about LENZ that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	63.95%
Earnings	—	—	—	7.26%
Analysts	—	—	—	8.16%
Announcements	—	—	—	17.01%
Controversies	—	—	—	0%
Macro	—	—	—	3.63%

Community

Of the messages about LENZ, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	66.67%	82.05%	17.46%
Newcomers	100%	33.33%	17.95%	82.54%

Aug 12

The company has reported strong Q2 performance, with a 45%+ increase in July prescriptions and $220M in liquidity, leading to a nearly 30% opening spike, but the move was sold back to flat, indicating a private institutional brawl rather than institutional confidence.
The analyst Biren Amin from Piper Sandler downgraded the target from $12 to $7, citing a decrease in potential upside, but the criticism is directed at Citi and Piper for not explaining how they incorporate patient-level cohort persistence and July prescriptions in their valuation.
The company's $3B US model is built on two variables: 128M presbyopes and 5 monthly packs, and Q2 provided empirical support for the utilisation assumption, showing that retained patients are behaving as the model requires, with more than 60% of ePharmacy patients purchasing multiple packs.

Generated by AI

News

LENZ Therapeutics: Below Cash For A Reason (NASDAQ:LENZ)

4d agoSeeking Alpha

Presbyopia Market Expected to Transform with Next-Generation Therapies and Strong Growth Through 2036 – DelveInsight | AbbVie, Orasis Pharma, Eyenovia, Glaukos Corp., Ocuphire Pharma, Novartis

5d agoBarchart.com

LENZ Therapeutics: Still Speculative But Priced For Disasters (NASDAQ:LENZ)

25d agoSeeking Alpha

LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts

The analyst fair value estimate for LENZ Therapeutics has shifted from US$32.00 to about US$26.83 per share, which now lines up more closely with the US$7 price target cluster that many firms reference. This reset reflects the more cautious stance in recent research, where several analysts cut price targets and moved to Neutral while they reassess the VIZZ launch and the company’s cash support. As you read on, you will see how these moving targets shape the evolving LENZ Therapeutics...

1mo agoYahoo Finance

Lenz stock drops as Bank of America downgrades (LENZ:NASDAQ)

1mo agoSeeking Alpha

Also Discussed

Investors talking about LENZ also mention

#	Name	Attention
1	Caribou Biosciences, Inc.CRBU	0%0
2	Intellia Therapeutics, Inc.NTLA	0%+0
3	Tarsus Pharmaceuticals Inc.TARS	0%new
4	Nkgen Biotech Inc.NKGN	0%0
5	FutureFuel Corp.FF	0%0
6	Nuvation Bio Inc.NUVB	0%0
7	Shattuck Labs, Inc.STTK	0%new
8	Beam Therapeutics IncBEAM	0.02%+0.02
9	Connect Biopharma Holdings LimitedCNTB	0%+0
10	Keros Therapeutics, Inc.KROS	0%new

LENZ Therapeutics, Inc.

Healthcare
Biotechnology

LENZ Therapeutics, Inc. is a pharmaceutical and biotechnology company focused on commercializing ophthalmic treatments that improve vision. Its primary product is VIZZ, an aceclidine-based eye drop approved for the treatment of presbyopia, the age-related loss of near vision. The company develops eye-care therapies designed for convenient daily use, with an emphasis on preservative-free, single-use formulations that support patient adherence and ease of administration. LENZ Therapeutics serves the prescription eye-care market and concentrates on addressing a common vision condition affecting adults worldwide. Headquartered in Solana Beach, California, the company plays a specialized role in the broader ophthalmology and biopharmaceutical sectors by bringing non-surgical treatment options to market for presbyopia management.

Website

Location

201 Lomas Santa Fe Drive

Solana Beach, CA, 92075

United States

Social

What share of all stock conversation is about LENZ?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Aug 12

LENZ Therapeutics, Inc. reported strong Q2 performance, with prescriptions increasing 8-10% quarter-over-quarter and 36-46% annualized growth.
The company's earnings call showed a 45% month-over-month increase in July prescriptions, with 60% of customers buying multiple packs.
Analyst Biren Amin downgraded LENZ's price target from $12 to $7, citing a decrease in potential upside change and a rating of Neutral.

Generated by AI

Sentiment

Of the messages about LENZ that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	50%	80% +0.83	75.68% -15.57
Bearish	0%	50%	20% -0.83	24.32% +15.57

Mar 15

LENZ Therapeutics, Inc. has a major uptrend on all technicals, with a strong possibility of reaching $5.
The company's merger is complete, a dividend is being paid out, and shorts have to pay $1.03 per short share, making it a favorable situation for the stock.
The FDA approval of LENZ's phase 3 results could significantly increase the stock's value, potentially exceeding $3, and investors should hold onto the stock for at least 1-2 years to reap the benefits.

Generated by AI

Topics

Of the messages about LENZ that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	63.95%
Earnings	—	—	—	7.26%
Analysts	—	—	—	8.16%
Announcements	—	—	—	17.01%
Controversies	—	—	—	0%
Macro	—	—	—	3.63%

Community

Of the messages about LENZ, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	66.67%	82.05%	17.46%
Newcomers	100%	33.33%	17.95%	82.54%

Aug 12

The company has reported strong Q2 performance, with a 45%+ increase in July prescriptions and $220M in liquidity, leading to a nearly 30% opening spike, but the move was sold back to flat, indicating a private institutional brawl rather than institutional confidence.
The analyst Biren Amin from Piper Sandler downgraded the target from $12 to $7, citing a decrease in potential upside, but the criticism is directed at Citi and Piper for not explaining how they incorporate patient-level cohort persistence and July prescriptions in their valuation.
The company's $3B US model is built on two variables: 128M presbyopes and 5 monthly packs, and Q2 provided empirical support for the utilisation assumption, showing that retained patients are behaving as the model requires, with more than 60% of ePharmacy patients purchasing multiple packs.

Generated by AI

LENZ Therapeutics

Social

Aug 12

Mar 15

Aug 12

LENZ Therapeutics: Below Cash For A Reason (NASDAQ:LENZ)

Presbyopia Market Expected to Transform with Next-Generation Therapies and Strong Growth Through 2036 – DelveInsight | AbbVie, Orasis Pharma, Eyenovia, Glaukos Corp., Ocuphire Pharma, Novartis

LENZ Therapeutics: Still Speculative But Priced For Disasters (NASDAQ:LENZ)

LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript

LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts

Lenz stock drops as Bank of America downgrades (LENZ:NASDAQ)

Also Discussed

LENZ Therapeutics, Inc.

Company Information

Location

LENZ Therapeutics: Below Cash For A Reason (NASDAQ:LENZ)

Presbyopia Market Expected to Transform with Next-Generation Therapies and Strong Growth Through 2036 – DelveInsight | AbbVie, Orasis Pharma, Eyenovia, Glaukos Corp., Ocuphire Pharma, Novartis

LENZ Therapeutics: Still Speculative But Priced For Disasters (NASDAQ:LENZ)

LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript

LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts

Lenz stock drops as Bank of America downgrades (LENZ:NASDAQ)

Also Discussed

Social

Aug 12

Mar 15

Aug 12